



# Financial Tear Sheet

## Corporate Profile

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket's multi-platform development approach applies the well-established lentiviral virus, which we refer to as LVV, adeno-associated virus, which we refer to as AAV, gene therapy platforms.

## Primary IR Contact

Rocket Pharmaceuticals, Inc  
The Empire State Building

### Phone:

646-440-9100

### E-mail:

[info@rocketpharma.com](mailto:info@rocketpharma.com)

## Stock Performance

### RCKT (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$15.32</b>
Change (%)	0.00 (0.00%)

<b>Volume</b>	0
<b>52 Week High</b>	\$25.96
<b>52 Week Low</b>	\$9.56
<b>Market Cap</b>	\$679,491,667
<b>Rolling EPS</b>	-1.94
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	44,353,242
Data as of December 14, 2018 4:00 p.m. ET	

## Recent News & Events

November 30, 2018

[Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares](#)

November 27, 2018

[Rocket Pharmaceuticals Prices Public Offering of Common Stock](#)

November 27, 2018

[Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy \(RMAT\) and Fast Track Designations for](#)

There are currently no events scheduled.



## SEC Filings

Filing Date	Form
12/14/18	4
12/10/18	4
12/10/18	4
12/06/18	CT ORDER

## Corporate Governance

David P. Southwell	President and Chief Executive Officer
Rudolf A. Baumgartner, MD	Executive Vice President, Chief Medical Officer
Dale Ritter	Vice President, Finance & Chief Accounting Officer
Claudine Prowse, PhD	Vice President, Strategy, Corporate Development & IRO

*Data provided by Nasdaq. Minimum 15 minutes delayed.*